Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Somatostatinoma × palbociclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 57 Sarcoma 6 Squamous Cell Carcinoma of Head and Neck 5 Ovarian Neoplasms 5 Neoplasms 5 Neoplasm Metastasis 5 Sarcoma, Ewing 4 Lymphoma, Non-Hodgkin 4 Rhabdomyosarcoma 3 Rhabdoid Tumor 3 Osteosarcoma 3 Neuroblastoma 3 Multiple Myeloma 3 Medulloblastoma 3 Glioma 3 Carcinoma, Non-Small-Cell Lung 3 Wilms Tumor 2 Prostatic Neoplasms 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Melanoma 2 Lymphoma 2 Liposarcoma 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Head and Neck Neoplasms 2 Estrogen Receptor-positive Breast Cancer 2 Ependymoma 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Colonic Neoplasms 2

Interventions

Capecitabine 5 Temozolomide 4 Octreotide 3 Magnetic Resonance Spectroscopy 2 Leucovorin 2 Fluorouracil 2 Cisplatin 2 Bortezomib 2 Bevacizumab 2 vatalanib 1 temsirolimus 1 sapanisertib 1 romidepsin 1 regorafenib 1 pentetreotide 1 pazopanib 1 palbociclib 1 motesanib diphosphate 1 lutetium Lu 177 dotatate 1 irinotecan sucrosofate 1 gallium Ga 68 dotatate 1 dehydroftorafur 1 batifiban 1 aflibercept 1 Thalidomide 1 Sunitinib 1 Streptozocin 1 Specimen Handling 1 Sirolimus 1 Panobinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02806648 2018-01-23

PALBONET

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡